Mario Occhipinti/X
Jun 17, 2025, 15:30
Mario Occhipinti: Proud to Share Our Newly Published Cochrane Meta-Analysis
Mario Occhipinti, Thoracic Oncologist at the National Cancer Institute of Milan, shared a post on X:
“After hard work, I’m proud to share our newly published Cochrane meta-analysis!
Adjuvant EGFR-TKIs for resected stage I–III EGFR-mutant NSCLC: what does the evidence really say?”
Roberto Ferrara, Medical Oncologist, Researcher in Thoracic Oncology and Molecular Immunology at Vita-Salute San Raffaele University, shared Mario Occhipinti‘s post on X, adding:
“Can we spare adjuvant chemotherapy in resected EGFR NSCLC?
Probably no.
Our Cochrane metanalysis shows no OS difference with 1st/2nd gen EGFR TKI vs adj chemo.
Relapses during the EGFR TKIs drug off time were higher compared to adj chemo (45% vs 30%).”
Title: Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation
Journal: Cochrane Library
Authors: Mario Occhipinti, Martina Imbimbo, Roberto Ferrara, Vittorio Simeon, Giulia Fiscon, Corynne Marchal, Nicole Skoetz, Giuseppe Viscardi
More posts featuring Roberto Ferrara on OncoDaily.
cancer
Cochrane Library
Cochrane meta-analysis
Corynne Marchal
EGFR-mutant NSCLC
EGFR-mutated NSCLC
EGFR+ NSCLC
Giulia Fiscon
Giuseppe Viscardi
Mario Occhipinti
Martina Imbimbo
National Cancer Institute of Milan
Nicole Skoetz
NSCLC
OncoDaily
Oncology
Roberto Ferrara
TKIs
Vita-Salute San Raffaele University
Vittorio Simeon
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 17, 2025, 15:30
Jun 17, 2025, 14:35
Jun 17, 2025, 14:28